# Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

> **NCT03586284** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 51 (actual)

## Conditions studied

- Cytomegalovirus Anterior Uveitis

## Interventions

- **DRUG:** Valganciclovir Hydrochloride
- **DRUG:** Ganciclovir Sodium
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Topical placebo

## Key facts

- **NCT ID:** NCT03586284
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-15
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Funding discontinued.
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03586284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03586284, "Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03586284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*